Transcept Pharmaceuticals Inc. (TSPT: 8.22, 2.37, 40.51%) Transcept announced an exclusive license with Purdue Pharmaceuticals to commercialize Intermezzo, a sleep aid for treating Insomnia in the United States. If approved by the U.S. Food and Drug Administration (FDA: undefined, undefined, undefined%), Intermezzo could be first prescription sleep aid approved for use in the middle of the night when a patient awakens and cannot fall back asleep. Shares surged 33.6% in pre-market trading.